Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Synairgen (SNG)

Price 4.51p on 19-07-2024 at 16:30:01
Change -0.105p -2.21%
Buy 4.79p
Sell 4.50p
Buy / Sell SNG Shares
Last Trade: Buy 10,000.00 at 4.7871p
Day's Volume: 242,727
Last Close: 4.645p
Open: 4.51p
ISIN: GB00B0381Z20
Day's Range 4.50p - 4.51p
52wk Range: 3.65p - 10.62p
Market Capitalisation: £9m
VWAP: 4.594309p
Shares in Issue: 201m

Recent Trades History Synairgen (SNG)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 10,000 4.7871p Ordinary
15:29:52 - 19-Jul-24
Buy* 10,000 4.7871p Ordinary
14:59:51 - 19-Jul-24
Buy* 14,622 4.7871p Ordinary
14:39:17 - 19-Jul-24
Sell* 1,797 4.5321p Ordinary
13:15:59 - 19-Jul-24
Buy* 52,761 4.7175p Ordinary
13:10:41 - 19-Jul-24
Buy* 26 4.7842p Ordinary
12:19:02 - 19-Jul-24
Buy* 54 4.80p Ordinary
11:49:10 - 19-Jul-24
Sell* 5 4.35p SI Trade
11:25:43 - 19-Jul-24
Sell* 38,817 4.50p Automatic Execution
11:25:42 - 19-Jul-24
Sell* 50,402 4.51p Automatic Execution
11:25:42 - 19-Jul-24

Share Price History for Synairgen

Time period:
to
Date Open High Low Close Volume

Share News for Synairgen

IN BRIEF: Synairgen slashes costs and focuses on small hospital trials

27th Jun 2024 12:04

Synairgen PLC - South Hampton, England-based drug discovery and development company focused on combatting respiratory disease - In 2023, pretax loss narrowed to GBP9.7 million from GBP20.1 million a year prior. No revenue generated. Research & Development expenditure down 56% to GBP6.5 million from GBP14.9 million. Other administrative expenses fell 30% to GBP3.8 million from GBP5.4 million. Cash and cash equivalents held at GBP10.5 million, down 34% from GBP15,9 million. Read More

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

7th May 2024 09:51

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday: Read More

IN BRIEF: Synairgen names Phytome's Joseph Colliver as CFO

11th Oct 2023 11:19

Synairgen PLC - Southampton, England-based drug discovery and biotechnology firm developing SNG001 antiviral treatment for lung infections - Appoints Joseph Colliver as chief financial officer with effect from November 6. Current CFO John Ward will step down from his role on November 3. Colliver has previously held CFO and senior commercial roles at Sativa Group Inc, and within the Kantar division of WPP PLC. He is currently CFO at Phytome Life Sciences Ltd, a pharmaceutical manufacturing firm focused on plant-based medicines. Read More

Synairgen promotes Marcin Mankowski to chief medical officer

3rd Oct 2023 09:59

(Alliance News) - Synairgen PLC on Tuesday promoted Marcin Mankowski to chief medical officer, effective immediately. Read More

IN BRIEF: Synairgen narrows interim loss on reduced R&D spending

21st Sep 2023 13:48

Synairgen PLC - Southampton, England-based drug discovery and biotechnology firm developing SNG001 antiviral treatment for lung infections - Pretax loss narrows to GBP5.2 million in six months that ended June 30 from GBP14.0 million a year before. Has no revenue either year, but research and development spending is reduced to GBP3.5 million from GBP11.1 million, as phase 3 Sprinter trial of SNG001 is mostly completed in 2022. Since the start of the second half, receives GBP2.4 million R&D tax credit, which adds to GBP14.6 million cash balance on June 30. Read More

FTSE 100 Latest
Value8,155.72
Change-49.17

Login to your account

Forgot Password?

Not Registered